SXTC — China SXT Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00HealthcareSpeculativeMicro CapNeutral
- $12.53m
- -$0.95m
- $2.60m
Annual income statement for China SXT Pharmaceuticals, fiscal year end - March 31st, USD millions except per share, conversion factor applied.
2018 March 31st | 2019 March 31st | 2020 March 31st | 2021 March 31st | 2022 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 20-F | 20-F | 20-F | 20-F |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 7.02 | 7.01 | 5.16 | 4.78 | 2.6 |
| Cost of Revenue | |||||
| Gross Profit | 3.4 | 4.61 | 2.7 | 2.84 | 1.25 |
| Selling / General / Administrative Expenses | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 5.39 | 5.24 | 12.1 | 6.97 | 7.79 |
| Operating Profit | 1.63 | 1.77 | -6.97 | -2.2 | -5.19 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 1.63 | 1.79 | -10.4 | -2.94 | -5.41 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 1.19 | 1.54 | -10.3 | -2.75 | -5.74 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 1.19 | 1.54 | -10.3 | -2.75 | -5.74 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 1.19 | 1.54 | -10.3 | -2.75 | -5.74 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 4 | 5.99 | -21.5 | -3.82 | -5.52 |
| Dividends per Share |